About LB Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://lbpharma.us/
Frequently Asked Questions
What is the 52-week range for LBRX?
The 52-week high is $50.16 and the 52-week low is $14.317.
What is the P/E ratio for LBRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for LBRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -25.91%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.87.
Analyst Recommendation Trends
Wall Street analyst consensus for LBRX over the last few months:
Latest LBRX News
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68
Needham analyst Ami Fadia initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $68.
LB Pharmaceuticals Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
https://www.sec.gov/Archives/edgar/data/1691082/000119312526410651/d171801ds3asr.htm
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals is a high-risk, high-reward play with sufficient cash showing early signals of benefit in the NOVA-1 trial. Read why LBRX stock is a buy.
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer. Dr. Kozauer is a leader in neuropsychiatric drug development with more than two decades of development expertise spanning early-stag
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
LB Pharmaceuticals (LBRX) has drawn fresh investor attention after appointing Joseph M. Miller as Chief Financial Officer. The announcement coincides with preparations for NOVA-2 trial readouts and a potential LB-102 launch in schizophrenia. Despite a pullback over the last day with a 1-day share price return of down 3.96% to US$47.52, LB Pharmaceuticals has delivered a 66.56% 90-day share price return and a 132.49% year-to-date share price return, which suggests that momentum has been...
LB Pharmaceuticals to Participate in Upcoming September Investor Events
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference 1x1 investor meetings on Wednesday, Septe
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer. Mr. Miller is a biopharmaceutical finance executive with more than two decades of experience leading financial strategy and operations and
LB Pharmaceuticals Appoints Joseph Miller CFO
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-30 | Deep Track Biotechnology Master Fund, Ltd. | +286,205 | $34.9399 | $9,999,974 |
| 2026-06-03 | Luse Rebecca | +10,000 | - | - |
| 2026-06-03 | Lenz Robert A. | +12,500 | - | - |
| 2026-06-03 | Kane William P Jr | +10,000 | - | - |
| 2026-06-03 | Hemrajani Rekha | +10,000 | - | - |
| 2026-06-03 | Nussbaum Ran | +10,000 | - | - |
| 2026-06-03 | Garland J. Scott | +10,000 | - | - |
| 2026-06-03 | RUFFOLO ROBERT R | +10,000 | - | - |
| 2026-03-06 | Lenz Robert A. | +20,000 | - | - |
| 2026-02-06 | KROIN DAVID | +93,925 | $21.1699 | $1,988,383 |
| 2026-02-06 | KROIN DAVID | +378,444 | $21.1699 | $8,011,622 |
| 2025-12-10 | Pai Panandiker Kaya Kamlesh | +195,000 | - | - |